Open AccessMesenchymal Stem Cells as a Biological Drug for Heart Disease
Author(s) -
Cristina Sanina,
Joshua M. Hare
Publication year - 2015
Publication title -
circulation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.899
H-Index - 336
eISSN - 1524-4571
pISSN - 0009-7330
DOI - 10.1161/circresaha.117.306306
Subject(s) - mesenchymal stem cell , regenerative medicine , clinical trial , medicine , stem cell , cell therapy , heart failure , stem cell therapy , disease , pharmacology , intensive care medicine , bioinformatics , pathology , biology , microbiology and biotechnology
Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom